We have recently shown that a VLP based on Hep B Surface antigen (Rv21) provided 100% sterile protection against P. berghei/Pv CSP transgenic sporozoite challenge in rodent malaria models [21] and this scenario indicates that it would be interesting to generate a P. cynomolgi–specific VLP to assess if relapse could be prevented. Here, DNAJC5 is linked to malaria.